Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not with severe disease features
Authors' conclusion
Anti-FHL1 autoantibodies are present in ∼11% of juvenile IIM patients and commonly co-occur with MAAs, including anti-Ro52 autoantibodies. In contrast to adult IIM, anti-FHL1 autoantibodies in juvenile myositis are associated with V-sign rash but not with other distinctive clinical features or worse outcomes.
Study context
- Population
- Large North American cohort of juvenile patients with IIM, and juvenile healthy controls
- Participants
- 338 vs 91
- Exposure
- Juvenile IIM vs juvenile healthy controls; anti-FHL1-positive vs negative juvenile IIM
- Juvenile IIMn = 338
- Controlsn = 91reference
- Outcome
- Prevalence of anti-FHL1 autoantibodies (ELISA) and associated clinical features
Methodological detailsELISA screening, HLA allele comparison
- ELISA screening
- HLA allele comparison
Main finding
As reported in the abstract
Anti-FHL1 autoantibodies present
Observational data: associations, not effects.
Further findings
Features associated with anti-FHL1 autoantibodies in juvenile IIM
- Myositis-associated autoantibodies (MAAs), OR
- 2.09 (1.03, 4.32) (CI)
- Anti-Ro52 autoantibodies, OR
- 4.17 (1.83, 9.37) (CI)
- V-sign rash, OR
- 2.59 (1.22, 5.40) (CI)
- Frequency did not differ among clinical and serologic subgroups
- No differences in other features or markers of disease severity
Anti-FHL1 autoantibodies by ethnicity: Asian patients higher
- Higher percentage of Asian patients had anti-FHL1 autoantibodies
- 11% vs 0.7%; P = 0.002
HLA associations in Caucasian myositis patients
- No HLA associations with anti-FHL1 autoantibodies identified
Original publication
Anti-FHL1 autoantibodies in juvenile myositis are associated with anti-Ro52 autoantibodies but not with severe disease features. Rheumatology (Oxford). Published 12 August 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →